2026-2034年全球罕見腎臟病治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，罕見腎臟病治療市場規模將從 2025 年的 38.2 億美元成長至 65.9 億美元，並預計從 2026 年到 2034 年將以 6.23% 的複合年成長率成長。

受人們對罕見腎病認知度提高和診斷技術進步的推動，全球罕見腎病治療市場正經歷顯著成長。局部性節段性腎絲球硬化症和非典型溶血性尿毒症候群等疾病需要特殊的治療方法。基因檢測和生物標記識別技術的進步使得早期診斷和更精準的診斷成為可能。此外，孤兒藥研發投入的增加也進一步促進了市場的擴張。

關鍵成長要素包括有利於孤兒藥核准的法規結構。生物製藥公司正專注於標靶治療和生物製藥，以滿足未被滿足的醫療需求。病患支持活動的活性化和罕見疾病研究經費的增加正在加速臨床試驗的進行。此外，已開發國家醫療保健服務的改善也促進了治療方法的廣泛應用。

隨著個人化醫療和基因療法的不斷發展，未來前景一片光明。新興市場正逐步建立罕見疾病管理基礎設施。研究機構與製藥公司之間的策略合作將加速創新。隨著全球認知度和診斷能力的提升，罕見腎臟病治療市場預計將持續顯著成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球罕見腎病治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 酵素替代療法
• 單株抗體
• 其他

第5章：全球罕見腎臟疾病治療市場：依適應症分類

• 市場分析、洞察與預測
• 法布瑞氏症
• 非典型溶血性尿毒症候群
• 狼瘡性腎炎
• 腎源性胱胺酸症
• 其他

第6章：全球罕見腎臟病治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 線上銷售

第7章 全球罕見腎臟病治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Calliditas Therapeutics AB
  • GSK Plc
  • Aurinia Pharmaceuticals Inc
  • Amicus Therapeutics Inc
  • Shire（Takeda Pharmaceutical Company Limited）
  • Sanofi
  • Advicenne
  • Alexion Pharmaceuticals Inc
  • Horizon Therapeutics Plc
  • Otsuka Pharmaceutical Co. Ltd
  • Reata Pharmaceuticals Inc

The Rare Kidney Diseases Treatment Market size is expected to reach USD 6.59 Billion in 2034 from USD 3.82 Billion (2025) growing at a CAGR of 6.23% during 2026-2034.

The Global Rare Kidney Diseases Treatment Market is witnessing notable growth driven by increasing awareness and improved diagnosis of rare renal disorders. Conditions such as focal segmental glomerulosclerosis and atypical hemolytic uremic syndrome require specialized therapies. Advancements in genetic testing and biomarker identification are enabling earlier and more accurate diagnoses. Rising investments in orphan drug development are further supporting market expansion.

Key growth drivers include supportive regulatory frameworks that provide incentives for orphan drug approvals. Biopharmaceutical companies are focusing on targeted therapies and biologics to address unmet medical needs. Increasing patient advocacy and funding for rare disease research are accelerating clinical trials. Additionally, improved healthcare access in developed countries is enhancing treatment availability.

Future prospects are promising as personalized medicine and gene therapies continue to evolve. Emerging markets are gradually improving rare disease management infrastructure. Strategic partnerships between research institutions and pharmaceutical firms will accelerate innovation. As awareness and diagnostic capabilities expand globally, the rare kidney diseases treatment market is expected to experience sustained and meaningful growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Enzyme Replacement Therapy
• Monoclonal Antibodies
• Others

By Indication

• Fabry Disease
• Atypical Hemolytic Uremic Syndrome
• Lupus Nephritis
• Nephropathic Cystinosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

COMPANIES PROFILED

• Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals Inc, Amicus Therapeutics Inc, Shire Takeda Pharmaceutical Company Limited, Sanofi, Advicenne, Alexion Pharmaceuticals Inc, Horizon Therapeutics plc, Otsuka Pharmaceutical Co Ltd, Reata Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Enzyme Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Fabry Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Atypical Hemolytic Uremic Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lupus Nephritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nephropathic Cystinosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RARE KIDNEY DISEASES TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Calliditas Therapeutics AB
  • 9.2.2 GSK Plc
  • 9.2.3 Aurinia Pharmaceuticals Inc
  • 9.2.4 Amicus Therapeutics Inc
  • 9.2.5 Shire (Takeda Pharmaceutical Company Limited)
  • 9.2.6 Sanofi
  • 9.2.7 Advicenne
  • 9.2.8 Alexion Pharmaceuticals Inc
  • 9.2.9 Horizon Therapeutics Plc
  • 9.2.10 Otsuka Pharmaceutical Co. Ltd
  • 9.2.11 Reata Pharmaceuticals Inc